Heron Therapeutics (HRTX) Non-Current Debt (2016 - 2025)
Historic Non-Current Debt for Heron Therapeutics (HRTX) over the last 5 years, with Q3 2025 value amounting to $107.5 million.
- Heron Therapeutics' Non-Current Debt rose 33292.65% to $107.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.5 million, marking a year-over-year increase of 33292.65%. This contributed to the annual value of $25.0 million for FY2024, which is 314.47% up from last year.
- As of Q3 2025, Heron Therapeutics' Non-Current Debt stood at $107.5 million, which was up 33292.65% from $25.2 million recorded in Q1 2025.
- Heron Therapeutics' 5-year Non-Current Debt high stood at $107.5 million for Q3 2025, and its period low was $24.0 million during Q3 2023.
- Its 3-year average for Non-Current Debt is $35.0 million, with a median of $24.7 million in 2024.
- Data for Heron Therapeutics' Non-Current Debt shows a peak YoY increase of 33292.65% (in 2025) and a maximum YoY decrease of 313.33% (in 2025) over the last 5 years.
- Over the past 3 years, Heron Therapeutics' Non-Current Debt (Quarter) stood at $24.3 million in 2023, then rose by 3.14% to $25.0 million in 2024, then soared by 329.5% to $107.5 million in 2025.
- Its Non-Current Debt was $107.5 million in Q3 2025, compared to $25.2 million in Q1 2025 and $25.0 million in Q4 2024.